hypogonadism%20in%20males%20-%20late-onset
HYPOGONADISM IN MALES - LATE-ONSET
Late onset hypogonadism is defined as clinical and biochemical syndrome characterized by older age, set of typical symptoms, and deficiency in serum testosterone levels.
The quality of life may be decreased and multiple organ systems may be adversely affected.
Prior to the start of testosterone substitution, there should be confirmation of low serum testosterone and a confirmation of need based on clinical findings.
Only if the potential benefit exceeds the risk, then replacement testosterone should be started.

Hypogonadism%20in%20males%20-%20late-onset Management

Follow Up

  • The patient should be monitored carefully (by monthly check-up every 3 months) for the development of adverse effects

At 1 Month & 3 monthly therafter

  • Follow up w/ patients to assess that the desired testosterone level is achieved
    • Optimal serum testosterone level for efficacy is unknown
    • It is generally recommended that mid to lower young adult levels may be appropriate as the therapeutic goal 
  • Evaluate the patient for complications/adverse effects & determine if symptoms are improving

During 1st Year of Therapy

  • Perform prostate exam, PSA, hematocrit every 3 months
    • Hematocrit >54% requires dose reduction or temporary medication discontinuation
    • If the PSA increases >0.75 ng/mL over 2 consecutive controls or a PSA level abnormal for age (>4 ng/mL), further exam & eventual biopsy may be needed
  • Plasma lipid determinations at the 3rd & 6th month of therapy
  • Liver function test, urinalysis & measurement of bone markers may be done at the 6th month

At 1 Year

  • Repeat all previous tests done on the 6th month
  • Blood glucose control should be evaluated by fasting blood glucose (FBG), post-prandial glucose (PPG) or HbA1c
  • After the 1st year, follow-up may be done every 6 months for 2 years & annually thereafter
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 2 days ago
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
06 Sep 2020
Type 2 diabetes mellitus patients taking proton pump inhibitors (PPIs) are at a higher risk of sustaining hip fractures, a recent study has found.
4 days ago
Osteoarthritis (OA) is the most common condition affecting the joints. Dr Lee Eu Jin, an Orthopaedic Surgeon from Liberty Orthopaedic Clinic at Mount Elizabeth Medical Centre, Singapore, shares his insights with Pearl Toh on how to manage OA in the primary care setting.


3 days ago
XOFLUZA – Baloxavir marboxil 20 mg and 40 mg FC tab